Resources
9 Results (showing 1 - 9)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 3/21/2022 (updated 3/27/2024)
People who inject drugs (PWID) are likely to experience wounds and infection related to their injection drug use. Common wounds and infections experienced by PWID include blood poisoning (septicemia), infection of the heart lining (endocarditis), tetanus, hepatitis, bruising, collapsed veins, abscesses and blood clots. Preventing and caring for wounds in PWID requires special consideration of the conditions surrounding drug use.
Posted 7/12/2022 (updated 3/27/2024)
Syringe services programs (SSP) are harm reduction programs that provide a wide range of services including, but not typically limited to, the provision of new, unused hypodermic needles and syringes and other injection drug use supplies, such as cookers, tourniquets, alcohol wipes, and sharps waste disposal containers, to people who inject drugs. In this summary, readers will find information with respect to SSPs for each state, including citations to applicable statutes and/or regulations, whether the state allows SSPs by statute, whether there are any municipal or county ordinances or regulations in place within the state, program components, miscellaneous provisions, and information on any pending legislation.
Posted 3/14/2023 (updated 3/27/2024)
Xylazine is a non-opioid that is approved for animals, and not FDA-approved for humans. New York State's Department of Health provides information on what it is, sources and trends, effects, why people use it, why clinicians should be concerned, and other information on Xylazine. Information about Xylazine is important to understand now that it has been showing up in illicit drug supply.
Posted 8/18/2020 (updated 3/28/2024)
This guide was created for harm reduction medical staff and volunteers as a resource about the types of wounds common with injection drug use and also to increase knowledge about treatment modalities for this population. Skin and soft-tissue infections are the most common cause of hospitalization among people who inject drugs.
Posted 11/27/2019 (updated 3/28/2024)
This guide is aimed at people who inject drugs to help reduce some of the problems caused by injecting.
Posted 10/12/2020 (updated 3/29/2024)
This report summarizes current (as of 2011) guidelines or recommendations published by multiple agencies of the U.S. Department of Health and Human Services (DHHS) for prevention and control of human immunodeficiency virus (HIV) infection, viral hepatitis, sexually transmitted diseases (STDs), and tuberculosis (TB) for persons who use drugs illicitly.
Posted 3/29/2024
A planning committee of the National Academies of Sciences, Engineering, and Medicine organized and conducted a two-day virtual public workshop that brought together data experts, program implementers and evaluators, and other key interested parties to explore data collection efforts, evidence gaps, and research needs on harm reduction for people who use drugs (PWUD).
Posted 7/28/2021 (updated 4/2/2024)
The most effective treatments for opioid use disorder (OUD) are the three prescription medications approved by the U.S. Food and Drug Administration (FDA)—methadone, buprenorphine, and naltrexone—that are proved to increase a patient’s treatment retention and reduce illicit use and the risk of overdose. The only facilities legally able to offer all three medications are opioid treatment programs (OTPs), a critical component of the U.S. substance use treatment system that are regulated by the federal Drug Enforcement Administration (DEA) and Substance Abuse and Mental Health Services Administration (SAMHSA), as well as state agencies, and are certified to administer any FDA-approved medication for the treatment of OUD.
Posted 8/4/2021 (updated 4/2/2024)
This session provided an opportunity to learn how to encourage faith leaders how to engage in harm reduction activities.